Project Grant R01CA299220
Award Date 3/23/26
Completion Date 2/28/31
Dollars Obligated $694K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
- Federal Grant Award Summary Tufts University School of Medicine received a $883,825.75 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) on May 15, 2025. This research initiative leverages existing leukocyte deoxyribonucleic acid (DNA) methylation data to identify biological pathways linking obesity to 13 distinct cancer types. The project utilizes data from the Atherosclerosis Risk in Communities Study (ARIC) to...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Institute For Cancer Research a Project Grant of $766,439 under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period April 1, 2026 through March 31, 2031. This research project focuses on intratumor heterogeneity as a correlate of clinical outcomes in bladder cancer patients pursuing cystectomy avoidance strategies. The primary deliverables include: (1) scientific investigation into the genetic...
- Federal Grant Award Summary Mayo Clinic received a $676,067 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on March 13, 2026, with a completion date of February 28, 2031. This project addresses thyroid cancer overdiagnosis by developing and validating artificial intelligence (AI) and natural language processing (NLP) systems to identify and characterize incidental thyroid nodules (ITNs) in imaging reports. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...
- Federal Grant Award Summary The National Cancer Institute awarded a $403,686 Project Grant to the University of California, Irvine under the Cancer Treatment Research program (CFDA 93.395) effective March 19, 2026, with a completion date of February 28, 2027. This research initiative will develop and validate a genetic screening approach to identify synergistic drug-diet interactions that enhance cancer therapy efficacy. The principal deliverables include the establishment of an unbiased,...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded the University of Connecticut a $444,991 Project Grant effective May 1, 2026 through April 30, 2030 to conduct a randomized controlled trial of a dissonance-based sun safety intervention targeting young adult tanners. The research will develop and evaluate a scalable intervention leveraging cognitive dissonance theory—an approach successfully...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a $156,500 Project Grant on August 1, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct integrated multi-omics research exploring the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The two-year project, concluding July 31, 2027, will investigate the systemic biological mechanisms underlying cancer cachexia through comprehensive analysis of...